nach oben

Erschienen in:

2024 | OriginalPaper | Buchkapitel

21. Postmenopausale Osteoporose und Osteoporose des Mannes über 50 Jahre

verfasst von : Bernhard Rintelen

Erschienen in: Rheumatologie aus der Praxis

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Osteoporose ist eine systemische Skeletterkrankung, die durch eine verminderte Knochenfestigkeit charakterisiert ist. Personen mit einer Osteoporose sind für ein erhöhtes Frakturrisiko prädisponiert [6]. Sie ist charakterisiert durch eine erniedrigte Knochendichte und gestörte Mikroarchitektur des Knochens. Dadurch bricht der Knochen leichter, oftmals schon durch ein niedrigenergetisches Trauma.

Vorheriges Kapitel Fingerpolyarthrosen

Nächstes Kapitel Rheuma und rheumatologische Pharmakotherapie in der Schwangerschaft

Beauchet O, Fantino B, Allali G, Muir SW, Montero-Odasso M, Annweiler C (2011) Timed up and go test and risk of falls in older adults: a systematic review. J Nutr Health Aging 15(10):933–938CrossRefPubMed

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243–254CrossRefPubMed

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972–980CrossRefPubMed

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523CrossRefPubMed

Carey JJ, Buehring B (2018) Current imaging techniques in osteoporosis. Clin Exp Rheumatol 36 Suppl 114(5):115–126PubMed

Consensus Development Conference (1991) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 90:107–110CrossRef

Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177(6):575–580CrossRefPubMedPubMedCentral

Dimai HP, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Fahrleitner-Pammer A, Pietschmann P, Muschitz C, McCloskey EV, Kanis JA (2022) Osteoporosis treatment in Austria-assessment of FRAX-based intervention thresholds for high and very high fracture risk. Arch Osteoporos 17(1):141CrossRefPubMedPubMedCentral

Dimai HP, Muschitz C, Amrein K, Bauer R, Cejka D, Gasser RW, Gruber R, Haschka J, Hasenöhrl T, Kainberger F, Kerschan-Schindl K, Kocijan R, König J, Kroißenbrunner N, Kuchler U, Oberforcher C, Ott J, Pfeiler G, Pietschmann P, Puchwein P, Schmidt-Ilsinger A, Zwick RH, Fahrleitner-Pammer A (2024) Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024) : Leitlinie der Österreichischen Gesellschaft für Knochen- und Mineralstoffwechsel [Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research]. Wien Klin Wochenschr. 2024(Suppl 16):599–668. German. https://doi.org/10.1007/s00508-024-02441-2. Epub 2024 Oct 2. PMID: 39356323.

10.

https://leitlinien.dv-osteologie.org/. Zugegriffen am 06.04.2024

11.

Elbers LPB, Raterman HG, Lems WF (2021) Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81(14):1645–1165CrossRefPubMedPubMedCentral

12.

Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313CrossRefPubMedPubMedCentral

13.

FRAX. https://frax.shef.ac.uk/FRAX/tool.aspx?lang=de. Zugriffsdatum 06.04.2024

14.

Gartlehner G, Patel SV, Reddy S, Rains C, Schwimmer M, Kahwati L (2022) Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US preventive services task force. JAMA 328(17):1747–1176CrossRefPubMed

15.

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148CrossRefPubMed

16.

Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17(1):58CrossRefPubMedPubMedCentral

17.

Hoffmann I, Shojaa M, Kohl M, von Stengel S, Becker C, Gosch M, Jakob F, Kerschan-Schindl K, Kladny B, Clausen J, Lange U, Middeldorf S, Peters S, Schoene D, Sieber C, Tholen R, Thomasius F, Bischoff-Ferrari HA, Uder M, Kemmler W (2022) Exercise reduces the number of overall and major osteoporotic fractures in adults. Does supervision make a difference? Systematic review and meta-analysis. J Bone Miner Res 37(11):2132–2148CrossRefPubMed

18.

Jin YZ, Lee JH (2016) Effect of brace to osteoporotic vertebral fracture: a meta-analysis. J Korean Med Sci 31(10):1641–1649CrossRefPubMedPubMedCentral

19.

Kanis JA et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22(3):809–816CrossRefPubMed

20.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16(6):581–589CrossRefPubMed

21.

Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899CrossRefPubMed

22.

Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82CrossRefPubMedPubMedCentral

23.

Kantor SM, Ossa KS, Hoshaw-Woodard SL, Lemeshow S (2004) Height loss and osteoporosis of the hip. J Clin Densitom 7(1):65–70CrossRefPubMed

24.

LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049–2102CrossRefPubMedPubMedCentral

25.

Malle O, Borgstroem F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP (2021) Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture – results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Bone 142:115071CrossRefPubMed

26.

McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R, O'Kelly J, Papapoulos S (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251–259CrossRefPubMed

27.

Muschitz C, Hummer M, Grillari J, Hlava A, Birner AH, Hemetsberger M, Dimai HP (2022) Epidemiology and economic burden of fragility fractures in Austria. Osteoporos Int 33(3):637–647CrossRefPubMed

28.

Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30(4):705–720CrossRefPubMedPubMedCentral

29.

Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA (2005) Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20(1):131–140PubMed

30.

Rodriguez AJ, Fink HA, Mirigian L, Guañabens N, Eastell R, Akesson K, Bauer DC, Ebeling PR (2017) Pain, quality of life, and safety outcomes of kyphoplasty for vertebral compression fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 32(9):1935–1944CrossRefPubMed

31.

Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24(7):1299–1307CrossRefPubMed

32.

Salonen L, Kivelä SL (2012) Eye diseases and impaired vision as possible risk factors for recurrent falls in the aged: a systematic review. Curr Gerontol Geriatr Res 2012:271481CrossRefPubMedPubMedCentral

33.

Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, FLEX Research Group (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976–982CrossRefPubMed

34.

Siehe Fachinformation der Präparate (Austria Codes Fachinformation, Apothekerverlag, Erscheinungsdatum 01.09.2024)

35.

Vellucci R, Terenzi R, Kanis JA, Kress HG, Mediati RD, Reginster JY, Rizzoli R, Brandi ML (2018) Understanding osteoporotic pain and its pharmacological treatment. Osteoporos Int 29(7):1477–1491CrossRefPubMed

36.

Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC (2018) Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force. JAMA 319(24):2532–2551CrossRefPubMed

37.

Wilson N, Hurkmans E, Adams J, Bakkers M, Balážová P, Baxter M, Blavnsfeldt AB, Briot K, Chiari C, Cooper C, Dragoi R, Gäbler G, Lems W, Mosor E, Pais S, Simon C, Studenic P, Tilley S, de la Torre J, Stamm TA (2020) Prevention and management of osteoporotic fractures by non-physician health professionals: a systematic literature review to inform EULAR points to consider. RMD Open 6(1):e001143CrossRefPubMedPubMedCentral

38.

World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization

Titel: Postmenopausale Osteoporose und Osteoporose des Mannes über 50 Jahre
verfasst von: Bernhard Rintelen
Verlag: Springer Berlin Heidelberg
Buch: Rheumatologie aus der Praxis
Print ISBN: 978-3-662-69692-7

Electronic ISBN: 978-3-662-69693-4

Copyright-Jahr: 2024
DOI: https://doi.org/10.1007/978-3-662-69693-4_21

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten